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Background. Epstein-Barr virus (EBV)-related smooth muscle neoplasms (SMNs) have been associated with immune
dysregulation, most notably in patients who have undergone solid organ transplantation or in patients with HIV/AIDS.
Objective. to report our experience with EBV-related neoplasms as well as describing the ﬁrst EBV-related SMN in the setting of
administration of glucocorticoids and the tumor necrosis factor inhibitor etanercept. Design. We have case reports, of minimum
3-year follow-up, 2002–2005. Setting. It was held in an academic and tertiary referral cancer center. Patients. Patients are
with dysregulated immunity after solid organ transplantation, HIV/AIDS, or with psoriasis after treatment with etanercept.
Interventions.Therewerediscontinuationofetanercept,righthepatictrisegmentectomy,andchemotherapy.Measurements.W euse
survival as a measurement here. Results. Patients who were able to withstand reduction in immunosuppression survived. Surgical
resection or chemotherapy was successful in delaying progression of disease. Limitations. There was a relatively short follow-up for
theseslow-growingneoplasms.Conclusion.EBV-relatedSMNshavevariableaggressiveness.Whilechemotherapymayslowdisease
progression, resection and improving the host immune status provide the best opportunity for primary tumor control.
Copyright © 2008 Kimberly Moore Dalal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Immunocompromised patients have an increased incidence
of immunosuppression-associated malignancies. While un-
usual, smooth muscle neoplasms (SMNs), such as leiomy-
omas and leiomyosarcomas, occur at a greater frequency
in immune-dysregulated patients compared to the general
population [1, 2]. SMNs have been reported in immun-
odeﬁcient patients after solid organ transplants [2–5], with
acquired immune deﬁciency syndrome (AIDS) [6], or with
congenital conditions [7–10]. SMNs are strongly associated
with Epstein-Barr virus (EBV) [4, 6, 9].
We report three cases of EBV-associated SMN, one
in a patient with psoriasis who had received the tumor
necrosis factor (TNF) antagonist etanercept, and describe
our institution’s recent experience with this entity.
Patient 1. A 55-year-old Asian man presented in 2002
with hepatitis B, hypertension, penile carcinoma status
postresection and lymphadenectomy in 1988, and chronic
renal insuﬃciency. He had undergone cadaveric renal trans-
plant in 1994 and remained rejection free on cyclosporine,
azathioprine, mycophenolate mofetil, and prednisone.
In March 2002, he developed abdominal pain and
a 15-pound weight loss. Computed tomography (CT)
scans (7/02) revealed an unresectable 14cm caudate-based
mass; multiple pulmonary nodules were visualized. Alpha-
fetoprotein level was normal. Core needle biopsy demon-
strated a well-diﬀerentiated SMN. His immunosuppressive2 Sarcoma
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Figure 1: CT and PET scans of EBV-related SMN of liver. CT scan of the abdomen and pelvis (8/05) from Patient 3 revealed multiple
masses, mainly in the right lobe and involving segment 4. The largest mass measured 6.8 × 5.8cm and was located in the right inferior lobe
(a). FDG-PET (9/05) demonstrated areas of hypermetabolism in the inferior aspect of the right hepatic lobe (SUV max 5.7), and two other
neighboring foci (SUV max 5) (b).
therapy was not reduced because of the likelihood of trans-
plant rejection. The patient refused systemic chemotherapy.
By November 2002, he developed jaundice and increasing
debilitation. CT scan revealed rapid disease progression with
pulmonary metastases and ascites. He died later that month.
Patient 2. An 18-year-old woman diagnosed with con-
genital AIDS began to experience abdominal pain at age 11,
in 1995. Colonoscopy was initially negative, but laparoscopy
in 1997 revealed a well-diﬀerentiated SMN arising from the
rectosigmoid, unchanged in 1998 and 1999 on subsequent
colonoscopies. In October 2002, during an evaluation for
persistent abdominal pain and areﬂexia in the left ankle
and knee, magnetic resonance imaging (MRI) revealed
multiple abdominal and paraspinal masses. She underwent
resectionofthelumbarparaspinaltumorandrodplacement.
Pathology demonstrated an EBV-related SMN.
By 2003, CD4 count was 8, and viral load was 15000.
Medications included stavudine and lamivudine. She then
presented, wheel-chair bound, with fatigue and refractory
abdominalpain,weighing19kg.EasternCooperativeOncol-
ogy Group (ECOG) performance status was 4. CT scans
(3/03) demonstrated low-attenuation lesions in the liver
and a 9cm mass arising between the stomach and the
liver. She demonstrated marked clinical improvement after
starting doxorubicin in October 2003, and 5–10% decrease
in masses on reimaging. She interrupted therapy in mid
2004, starting dacarbazine in November 2004 for persistent
disease aﬀecting the chest, abdomen, and paraspinal areas.
Despite her noncompliance and neutropenia, the tumors
decreased in size further, her weight doubled, she began
to walk, and has an ECOG performance status of 1 as
of January 2006. She is still alive with disease (AWD)
but without progression as of last follow-up in October
2008.
Patient 3. The patient is a 25-year-old woman with
left kidney agenesis, history of psoriasis since childhood,
and seven episodes of shingles. In August 2004, she began
intravenous etanercept. One month later, she developed
left cervical lymphadenopathy and right lower extremity
numbness and tingling. A positive monospot test led to a
diagnosis of mononucleosis. Etanercept was discontinued;
her symptoms resolved. In October, she began prednisone
(40mg daily) treatment for increasing dyspnea attributed
to asthma; this was tapered oﬀ in January 2005 when she
saw her primary care provider and chest radiograph revealed
bilateral inﬁltrates. Chest CT demonstrated inﬁltrates and
three liver lesions. Lung biopsy revealed Pneumocystis carinii
pneumonia. CT scan (1/05) conﬁrmed three liver lesions,
the largest measuring 7cm with central necrosis. Fine needle
aspiration of a liver mass revealed a well-diﬀerentiated
SMN. CT scan (4/05) noted that the largest liver lesion
was 7.5cm in size. Subsequent CT scan (8/05) revealed no
change. Positron emission tomography (PET) scan (9/05)
showed tracer uptake in the liver lesions (Figure 1). In
October2005,sheunderwentanextendedrighthepatectomy
and cholecystectomy. Pathology revealed multicentric EBV-
associated SMNs (Figure 2). She remains without disease as
of October 2008.
2. METHODS
2.1. Lightmicroscopyand
immunohistochemistry(IHC)
Formalin-ﬁxed, paraﬃn-embedded tissue blocks were sec-
tioned (4μm) and stained with hematoxylin and eosin
for conventional histology. IHC analysis was performed
using standard techniques with the following antibodiesKimberly Moore Dalal et al. 3
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Figure 2: Gross and microscopic ﬁndings from EBV-related SMN of liver. Liver specimen from Patient 3 measured 17 × 13.2 × 7.6cm.
Four nodules were found, ranging in size from 0.4cm to 6.7cm (a). Histologic features on H&E staining included moderate increased
cellularity (with areas containing rounder, less fusiform cells), lack of nuclear pleomorphism, and a low mitotic rate (1 mitotic ﬁgure/50
high-powered ﬁeld) (b). Nearly all cells were positive for EBV-EBER by ISH, although intensity of the staining varied from cell to cell (c).
Electron microscopy revealed spindle cells with abundant cytoplasmic aggregates of actin microﬁlaments, including fusiform dense bodies
and attachment plaques, conﬁrming the diagnosis of a well-diﬀerentiated smooth muscle proliferation (d).
(prediluted from Ventana medical Systems Inc, Tucson, AZ,
USA, except where noted): HHF-35, smooth muscle actin
(SMA), desmin (DAKO, 1:50), CD117 (DAKO, 1:500), S100
protein (1:500, Dako, Glostrup, Denmark), and HMB-45.
2.2. InsituhybridizationforEBER
Detection of EBV-encoded early RNA transcripts (EBER
1 and 2) was performed using biotin-conjugated oligonu-
cleotides (PNA probe, Dako), using standard protocols
according to the manufacturer’s instructions. The positive
control used was a posttransplant EBV-associated diﬀuse
largecelllymphoma.AllstepswereperformedunderRN Ase-
free conditions.
2.3. Electronmicroscopy(EM)
Tissue for EM was available in Case 3. Representative fresh
tumor was ﬁxed in 3% formaldehyde—3% glutaraldehyde,
postﬁxed in 1% osmium tetroxide, embedded in epoxy resin,
and stained with uranyl acetate-lead citrate using standard
procedures.ThethinsectionswereexaminedusingaPhilips-
410 electron microscope.
3. RESULTS
3.1. Microscopicandelectronmicroscopicﬁndings
All patient samples were positive for EBV-EBER by ISH
(Figure 2), and the vast majority of cells were positive for
EBER by ISH. IHC from biopsies of the liver tumor from
Patient 1 was positive for SMA and desmin, but negative for
CD117 (ckit), HMB-45, and S-100. Histologic features from
the colonic SMN from Patient 2 included mild to moderate
increase in cellularity, low mitotic count (<1/10 HPF), and
no areas of necrosis. IHC was positive for desmin and SMA,
but negative for CD117 and S-100.
The liver specimen from Patient 3 revealed multicentric
EBV-associated SMNs consisting of four nodules ranging in
size from 0.4cm to 6.7cm (Figure 2). Moderate increased
cellularity (with areas of somewhat rounder, less fusiform
cells), focal areas of necrosis, lack of nuclear pleomorphism,
and low mitotic rate (1 mitotic ﬁgure/50 high-powered
ﬁeld) were noted. The tumors were positive for SMA,4 Sarcoma
Table 1: Three diﬀerent clinical scenarios in which EBV-related SMNs developed: patient summary. Dx = diagnosis. SMN = smooth muscle
neoplasm. DOD = dead of disease. AWD = alive with disease. NED = no evidence of disease.
# Age at Dx
(year)
Cause of immune
dysregulation
Date of start of
immune dysre-
gulation
Time to SMN Site Treatmen Status follow-up
1 55M
Cadaveric renal trans-
plant prednisone, cycl-
osporine, azathioprine,
mycophenolate mofetil
1994 8 years Liver (caudate
14cm); lung
Observation (decli-
ned systemic thera-
py) (7/02)
DOD 5 months
2 18F AIDS CD4 count = 8 Birth 11 years
Colon, chest,
paraspinal/ver-
t e b r a l ,l i v e r ,g l u -
teal, perigastric
areas
Antiretrovirals
doxorubicin, then
dacarbazine (10/03)
AWD without
progression, 5
years
3 25F Psoriasis, etanercept
therapy 20+ years, 8/04
20+ years, 5 months
after etanercept sta-
rted
Liver
Stopped immuno-
suppressives; hepatic
resection (10/05)
NED, 3 years
HHF35, desmin and negative for CD117. EM from Patient 3
revealed spindle cells with abundant cytoplasmic aggregates
of actin microﬁlaments, including fusiform dense bodies
and attachment plaques (Figure 2). Linear arrangements of
pinocytotic vesicles were noted in many cells. Cytoplasmic
organelles were mainly represented by mitochondria, while
rough endoplasmic reticulum cisternae were sparse. These
ultrastructural features conﬁrmed the diagnosis of a well-
diﬀerentiated SMN. No nuclear viral particles were detected.
4. DISCUSSION
Multiple lines of evidence implicate EBV in the formation of
SMNs [4, 8]. EBV DNA and RNA have been demonstrated
in SMNs in immunocompromised patients [4, 5] and in
our patients. Conversely, EBV is absent in sporadic smooth
muscletumorsinimmunocompetentpatients[7,11].Patho-
genesis appears to be related to infection and transformation
of smooth muscle cells by EBV; fusion of EBV-superinfected
lymphoblastoid cells and human embryonic ﬁbroblasts may
be the vehicle by which smooth muscle cells are infected
[12]. CD21 expression may play a role, in pathogenesis, as
CD21 has been described in 16 of 20 EBV-associated SMNs
in patients with AIDS [4, 6, 9]. Moreover, ﬁve to ten percent
of smooth muscle cells display strong immunoﬂuorescent
staining of CD21 [13]. Based on viral genomic analyses of
tumors, multifocal lesions appear to result from multiple
independent infection events rather than metastasis [14]. It
appearsthatthevirusisnotovertlyvirulent,sinceEBVseems
to eﬀect change in smooth muscle cells of immunocom-
promised patients rather than immunocompetent patients.
Perhaps this is why these tumors tend to be low grade.
Histologically, EBV-associated SMNs have a mild to
moderate increase in cellularity, low mitotic count (<1/10
HPF), and little to no areas of necrosis. Others have
reported foci of primitive-rounded cells and intratumoral
Tl y m p h o c y t e s[ 14, 15], but these were not seen in our
three cases. Immunohistochemically, SMNs stain positively
for desmin and SMA. On EM, SMNs demonstrate spindle
cells with abundant cytoplasmic actin microﬁlaments with
linearly arranged pinocytic vesicles. SMNs appear to be
relatively well diﬀerentiated with only a modest degree of
atypia [14].
In a literature review of 19 reports of EBV-associated
SMNs following organ transplantation [16], SMNs occurred
after a latency of one to six years as a single tumor, or more
often,asmultifocalormulticentriclesionsinmultipleorgans
[16]. The most common locations were liver, lung, heart,
and colon [16, 16–18]. As the behavior of SMNs appears
related to immune status rather than to speciﬁc histologic
features, the mainstay of treatment was the reduction of
immunosuppression; however, ﬁve of the seven patients who
survived with follow-up of 10 months to 12 years underwent
surgical resection [16].
Immunosuppression predisposes patients to the devel-
opment of SMNs, ﬁrst described 40 years ago [19]. Initially
reported, following renal transplantation and immunosup-
pression in the pediatric population, SMNs are observed in
patients after solid organ and stem cell transplants [2–5],
withAIDS[6],orwithcongenitalimmunodeﬁciency [7–10].
Reversal of immunosuppression, eﬀective in treatment of
posttransplant lymphoproliferative disorder, appears critical
to improved outcomes of EBV-associated SMNs [18]( e . g . ,
reduction or change of immunosuppressive agent in trans-
plant patients or use of famciclovir for high-risk patients
[17]).
In our case series, the three patients with SMNs were
immunodeﬁcient for diﬀerent reasons (Table 1).We describe
the ﬁrst EBV-associated SMN in a human patient receiving
etanercept, although immune dysregulation associated with
her psoriasis was more likely an important predisposing
condition. Etanercept competitively binds TNF to reduce
TNF activity from excessive inﬂammatory levels to normal
physiologic levels, eﬀectively treating rheumatoid arthritis
and psoriasis within months [20]. Known side eﬀects of
etanercept include an increased risk of lymphoma in these
patients [20–22], although it has been reported that long-
term treatment with TNF-alpha inhibitors does not increase
EBVloadinpatientswithrheumatoidarthritis[23].Psoriasis
patients treated with etanercept have also been diagnosedKimberly Moore Dalal et al. 5
with noncutaneous solid tumors, nonmelanoma skin cancer,
and melanoma as well as an increased risk of liver cancer
[24, 25]. Anti-TNF-alpha treatment has been associated with
vascular smooth muscle cell proliferation in a rabbit model
[26].
In summary, these cases highlight the variable aggres-
siveness and clinical outcomes of SMNs in patients
with immunosuppression on the basis of autoimmunity,
iatrogenic immunosuppression, and that caused by HIV.
Chemotherapy and surgery both play a role in patients with
these usually indolent diseases. It remains to be seen whether
eﬀects on EBV itself with antiviral agents or with EBV-
speciﬁcTcelltherapy[27]mighthavesalutaryeﬀectsagainst
t h i sr a r es o f tt i s s u en e o p l a s m .
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